William K. Oh, MD, discusses challenges with developing novel targeted agents in prostate cancer.
William K. Oh, MD
Advertisement
Articles by William K. Oh, MD
Advertisement
Latest Updated Articles
Dr. Oh on Recognizing Symptom Burden in Advanced Prostate CancerPublished: July 22nd 2016 | Updated:
Dr. Oh on the Role of Docetaxel in Metastatic Hormone-Sensitive Prostate CancerPublished: November 23rd 2016 | Updated:
Dr. Oh on the Safety Profile of Docetaxel in Prostate CancerPublished: January 6th 2017 | Updated:
Dr. Oh on Remaining Challenges With Docetaxel in Prostate CancerPublished: January 20th 2017 | Updated:
Dr. Oh Discusses the Role of Chemotherapy in Prostate CancerPublished: February 22nd 2017 | Updated:
Dr. Oh on the Sequencing of New Therapies for Prostate CancerPublished: February 24th 2017 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5